GlassScriptPhysician profile
Marissa Renee Gonzalez
NPI 1104053602
$8,536.68
in general payments reported to CMS, 2019-2025
41 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,166 · 2020: $744 · 2021: $1,526 · 2022: $1,300 · 2023: $860 · 2024: $1,446 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,801.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bolton Medical INC | $2,158.16 | 2019-2024 | Relay Thoracic Stent-Graft With Plus Delivery System |
| Kerecis Limited | $887.36 | 2019-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Angiodynamics, INC. | $619.66 | 2024-2025 | Auryon Laser System 100-120 Vac |
| Endologix LLC | $522.74 | 2019-2023 | Afx2 Bifurcated Endograft System |
| Astrazeneca Pharmaceuticals LP | $503.64 | 2019-2025 | Farxiga, Airsupra |
| Medtronic, INC. | $481.39 | 2021-2025 | Endurant Iis |
| Medtronic Vascular, INC. | $349.89 | 2019-2020 | |
| Lilly USA, LLC | $305.99 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Mimedx Group, INC. | $233.91 | 2024 | |
| Viiv Healthcare Company | $208.70 | 2019-2021 | |
| Glaxosmithkline, LLC. | $198.14 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Melinta Therapeutics, LLC | $161.53 | 2019-2023 | Kimyrsa |
| Alexion Pharmaceuticals, INC. | $160.02 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $159.09 | 2019-2023 | Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $133.10 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.